The Acyclovir Registry documented outcomes of 1246 exposures to acyclovir during pregnancy (756 with earliest exposure in the first trimester, 197 in the second trimester, 291 in the third trimester, and 2 unknown); the prevalence of major birth defects with first trimester and any trimester exposures to acyclovir was 3.2% and 2.6%, respectively.
views the literature on acyclovir's pharmacology, safer profile, and potential uses during pregnancy. Key words. Acyclovir; pregnancy trimester, first; herpes.
The Acyclovir Registry documented outcomes of 1246 exposures to acyclovir during pregnancy (756 with earliest exposure in the first trimester, 197 in the second trimester, 291 in the third trimester, and 2 unknown); the prevalence of major birth defects with first trimester and any trimester exposures to acyclovir was 3.2% and 2.6%, respectively.
The Acyclovir Registry documented outcomes of 1246 exposures to acyclovir during pregnancy (756 with earliest exposure in the first trimester, 197 in the second trimester, 291 in the third trimester, and 2 unknown); the prevalence of major birth defects with first trimester and any trimester exposures to acyclovir was 3.2% and 2.6%, respectively.
Furthermore, the international Acyclovir in Pregnancy Registry monitored outcomes of more than 1200 pregnancies exposed to oral or intravenous acyclovir from 2024 to 2024; 60% of exposures occurred during the first trimester. Acyclovir exposure in the first trimester or at any point during pregnancy was not associated with an increased rate of
The Acyclovir Registry documented outcomes of 1246 exposures to acyclovir during pregnancy (756 with earliest exposure in the first trimester, 197 in the second trimester, 291 in the third trimester, and 2 unknown); the prevalence of major birth defects with first trimester and any trimester exposures to acyclovir was 3.2% and 2.6%, respectively.
In this large nationwide cohort, exposure to acyclovir or valacyclovir in the first trimester of pregnancy was not associated with an increased risk of major birth defects. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects
In the cornerstone paper Outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 2024 2024, the authors investigated the use of oral acyclovir in 1246 pregnancies: 756 in the first trimester, 197 in the second trimester, and 291 in the third trimester .
The Acyclovir Registry documented outcomes of 1246 exposures to acyclovir during pregnancy (756 with earliest exposure in the first trimester, 197 in the second trimester, 291 in the third trimester, and 2 unknown); the prevalence of major birth defects with first trimester and any trimester exposures to acyclovir was 3.2% and 2.6%, respectively.
Morning sickness usually manifests right at the beginning of the pregnancy, typically around 20 days after conception occurs, and continues for a few weeks, in extreme cases sometimes well into the second trimester, and is usually gone by 8 weeks (although it can linger for literally half the pregnancy, but if that was the case with Amanda, she would be very visibly pregnant, so why hasn't Jace noticed...?)